Skip to main content
PMC home page
Diagnostics logoLink to Diagnostics
. 2021 May 31;11(6):1009. doi: 10.3390/diagnostics11061009

Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET/CT Imaging

Michael Winkelmann 1, Kai Rejeski 2, Marion Subklewe 2, Jens Ricke 1, Marcus Unterrainer 1, Martina Rudelius 3, Wolfgang G Kunz 1,*
Editor: Alessandro Stecco
PMCID: PMC8229233  PMID: 34073137

Abstract

The sarcoid-like reaction represents an autoinflammatory cause of mediastinal and hilar lymphadenopathy but may also involve other lymph node regions and organs. This rare phenomenon has mainly been reported in patients with Hodgkin’s lymphoma (HL) or solid tumors (particularly melanoma) undergoing immunotherapy and chemotherapy. Cases in non-Hodgkin’s lymphoma (NHL) are very uncommon. We present an uncommon case of a patient with primarily mediastinal diffuse large B-cell lymphoma (DLBCL) who showed a CT-based partial response in interim staging, whereas at end-of-treatment multiple newly enlarged and hypermetabolic mediastinal and bilateral hilar lymph nodes were detected by 18F-FDG PET/CT imaging. A subsequent histological workup determined a sarcoid-like reaction without any lymphomatous tissue. Therefore, sarcoid-like reactions should be considered as a potential pitfall in Deauville staging with 18F-FDG PET/CT imaging for patients with NHL.

Keywords: lymphoma, NHL, sarcoid-like reaction, PET/CT, pitfall, Deauville

The sarcoid-like reaction represents an autoinflammatory cause of mediastinal and hilar lymphadenopathy [1,2]. This rare phenomenon has mainly been reported in patients with solid tumors undergoing immunotherapy (particularly in those with melanoma), but can also be seen in patients treated with chemotherapy [3,4,5,6]. In addition to the involvement of regional lymph nodes, a sarcoid-like reaction can also affect distant lymph node regions or organs such as the lung, spleen, bone marrow, and skin [7,8]. Rare cases of sarcoid-like reactions have been reported in patients with HL [9,10,11]. Cases of sarcoid-like reactions in patients with NHL are less common [10,11,12]. Some authors propose the concept of a lymphoma-sarcoidosis syndrome, in which patients have a coexistence of sarcoidosis and lymphoma, particularly HL [13]. A study comparing the prognosis of patients presenting with DLBCL with and without sarcoidosis showed no significant difference in overall survival and progression-free survival between the two groups [14].

In this case (Figure 1), the occurrence of the newly appearing hypermetabolic mediastinal and bilateral hilar lymph nodes could have been misinterpreted as a Deauville score of 5 (DS 5). Lymphoma patients with a DS 5 show a poor prognosis and have a higher chance of relapse compared to a DS 4 [15,16].

Figure 1.

Figure 1

Open in a new tab

A 55-year-old male patient with primarily mediastinal diffuse large B-cell lymphoma (DLBCL; A) underwent 6 cycles of chemotherapy and 2 cycles of rituximab (R-CHOP-14). At interim staging after 3 cycles of therapy, CT-based partial response was achieved (B). After completion of therapy (C), staging was carried out using 18F-FDG PET/CT imaging for an additional assessment of metabolic response. The pre-existing mediastinal lymphoma manifestation continued to decrease significantly in size (C) in addition to a complete metabolic response (Deauville 2). At the same time, however, multiple newly enlarged and hypermetabolic mediastinal and bilateral hilar lymph nodes (SUVmax 17) were detected in locations previously unaffected by the DLBCL (C). These findings triggered a biopsy with endobronchial ultrasound and transbronchial needle aspiration. The following histological workup determined multiple epithelioid cell granulomas without any necrosis or lymphomatous tissue, which was compatible with a sarcoid-like reaction (E). The subsequent CT staging 3 months later without any further therapy showed a normalization in size of the mediastinal and bilateral hilar lymph nodes (D).

Overall, this case underlines the importance of the tissue biopsy of unclear newly appearing lesions in patients with lymphoma. In clinical routine, sarcoid-like reactions should be considered as a potential pitfall in Deauville staging with 18F-FDG PET/CT imaging, even in NHL patients and in cases with high metabolic activity.

Author Contributions

M.W., M.U., and W.G.K. designed research, analyzed data and wrote the manuscript. K.R., M.S., and M.R. provided clinical information and data for the figure. M.W., K.R., M.S., J.R., M.U., M.R., and W.G.K. reviewed the final manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Written informed consent has been obtained from the patient to publish this paper.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Gkiozos I., Kopitopoulou A., Kalkanis A., Vamvakaris I.N., Judson M.A., Syrigos K.N. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer. 2018;13:1076–1082. doi: 10.1016/j.jtho.2018.04.031. [DOI] [PubMed] [Google Scholar]
  • 2.Avram A.M., Mackie G.C., Schneider B.J., Kalemkerian G.P., Shulkin B.L. Differentiation between carcinoid and sarcoid with F-18 FDG PET and In-111 pentetreotide. Clin. Nucl. Med. 2006;31:197–200. doi: 10.1097/01.rlu.0000204200.66112.a9. [DOI] [PubMed] [Google Scholar]
  • 3.Cheshire S.C., Board R.E., Lewis A.R., Gudur L.D., Dobson M.J. Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma. Radiology. 2018;289:564–567. doi: 10.1148/radiol.2018180572. [DOI] [PubMed] [Google Scholar]
  • 4.Paya-Llorente C., Cremades-Mira A., Estors-Guerrero M., Martinez-Hernandez N., Alberola-Soler A., Galbis-Carvajal J.M. Mediastinal sarcoid-like reaction in cancer patients. Pulmonology. 2018;24:61–63. doi: 10.1016/j.pulmoe.2017.12.003. [DOI] [PubMed] [Google Scholar]
  • 5.Chowdhury F.U., Sheerin F., Bradley K.M., Gleeson F.V. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: Prevalence and disease pattern. Clin. Radiol. 2009;64:675–681. doi: 10.1016/j.crad.2009.03.005. [DOI] [PubMed] [Google Scholar]
  • 6.van Willigen W.W., Gerritsen W.R., Aarntzen E. 18F-FDG PET/CT of Multiorgan Sarcoid-Like Reaction During Anti-PD-1 Treatment for Melanoma. Clin. Nucl. Med. 2019;44:905–906. doi: 10.1097/RLU.0000000000002779. [DOI] [PubMed] [Google Scholar]
  • 7.Del Arco C.D., Acenero M.J. Sarcoid reaction: A rare occurrence associated to colon adenocarcinoma (case report and literature review) J. Gastrointest. Oncol. 2016;7:E72–E76. doi: 10.21037/jgo.2016.03.07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kurata A., Terado Y., Schulz A., Fujioka Y., Franke F.E. Inflammatory cells in the formation of tumor-related sarcoid reactions. Hum. Pathol. 2005;36:546–554. doi: 10.1016/j.humpath.2005.02.017. [DOI] [PubMed] [Google Scholar]
  • 9.Gebrekidan S., Schaller T., Rank A., Kircher M., Lapa C. Sarcoid-like reactions: A potential pitfall in oncologic imaging. Eur. J. Nucl. Med. Mol. Imaging. 2020 doi: 10.1007/s00259-020-04960-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Brincker H. Sarcoid reactions in malignant tumours. Cancer Treat. Rev. 1986;13:147–156. doi: 10.1016/0305-7372(86)90002-2. [DOI] [PubMed] [Google Scholar]
  • 11.Brincker H. Sarcoid reactions and sarcoidosis in Hodgkin’s disease and other malignant lymphomata. Br. J. Cancer. 1972;26:120–123. doi: 10.1038/bjc.1972.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Cho H., Yoon D.H., Kim J.H., Ko Y.B., Kwon B.S., Song I.H., Suh C. Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma. Korean J. Intern. Med. 2016;31:605–607. doi: 10.3904/kjim.2014.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Brincker H. The sarcoidosis-lymphoma syndrome. Br. J. Cancer. 1986;54:467–473. doi: 10.1038/bjc.1986.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chalayer E., Bachy E., Occelli P., Weiler L., Faurie P., Ghesquieres H., Pavic M., Broussolle C., Seve P. Sarcoidosis and lymphoma: A comparative study. QJM. 2015;108:871–878. doi: 10.1093/qjmed/hcv039. [DOI] [PubMed] [Google Scholar]
  • 15.Dunleavy K., Pittaluga S., Maeda L.S., Advani R., Chen C.C., Hessler J., Steinberg S.M., Grant C., Wright G., Varma G., et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N. Engl. J. Med. 2013;368:1408–1416. doi: 10.1056/NEJMoa1214561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Martelli M., Ceriani L., Zucca E., Zinzani P.L., Ferreri A.J., Vitolo U., Stelitano C., Brusamolino E., Cabras M.G., Rigacci L., et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J. Clin. Oncol. 2014;32:1769–1775. doi: 10.1200/JCO.2013.51.7524. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable.

Articles from Diagnostics are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES